This new position paper describes and analyses the current and potential applications and value creation of Generative AI for pharmaceutical companies.
News
Developing a strategy for rare diseases in France requires a clear understanding of the care ecosystem, key...
The French Voluntary Trade Organization (VTO) market is consolidating, making VTOs increasingly important partners for pharma companies...
« High-performance Market Access Brand Plans require method, rigor and pragmatism » Our new publication on how to build...